Stock GNFT GENFIT
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases GENFIT Euronext Paris

Equities

GNFT

FR0004163111

End-of-day quote Euronext Paris
Other stock markets
- PTS - Intraday chart for GENFIT
05-10 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
05-08 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
GENFIT : Shareholders Letter 16 - May 2024
PU
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
GL
GENFIT : Extra-Financial Performance Report 2024, 2023 Activity
PU
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
GL
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
GL
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
GL
GENFIT : Corporate presentation - Investor Events - April 2024
PU
GENFIT Announces Revenues and Cash Position as of December 31, 2023
GL
GENFIT Announces Revenues and Cash Position as of December 31, 2023
AQ
GENFIT Announces 2024 Financial Calendar  
GL
GENFIT Announces 2024 Financial Calendar  
AQ
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GL
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
GL
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
GL
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
GL
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
AQ
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
GL
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
AQ
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
GL
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GNFT Stock
  4. GNFT Stock
  5. News GENFIT
  6. Press Releases